Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV +1.75%35 PB Ratio is 0.85 as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,220 Biotechnology companies, Acrivon Therapeutics ranks better than 90.49% on this metric.
The historical rank and industry rank for Acrivon Therapeutics's PB Ratio or its related term are showing as below:
ACRV'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.72
Current: 0.71
During the past 6 years, Acrivon Therapeutics's highest PB Ratio was 0.72. The lowest was 0.00. And the median was 0.00.
ACRV's PB Ratio is ranked better than 90.49% of 1220
companies
in the Biotechnology industry
Industry Median: 2.905
vs ACRV: 0.71
During the past 12 months, Acrivon Therapeutics's average Book Value Per Share Growth Rate was -37.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.00% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Acrivon Therapeutics was -23.00% per year. The lowest was -23.00% per year. And the median was -23.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Acrivon Therapeutics PB Ratio Related Terms
Acrivon Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acrivon Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Acrivon Therapeutics (ACRV) has a PB Ratio of 0.85 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Acrivon Therapeutics and its competitors. According to the industry distribution chart, Acrivon Therapeutics ranks #116 out of 1220 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Acrivon Therapeutics' PB Ratio too high?
Acrivon Therapeutics' current PB Ratio is 0.85. The Biotechnology industry median PB Ratio is 2.91. Acrivon Therapeutics' value of 0.85 is 70.7% below this industry median. Based on the distribution chart, Acrivon Therapeutics ranks #116 out of 1220 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' PB Ratio compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #116 out of 1220 companies for PB Ratio. This places Acrivon Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.91. Acrivon Therapeutics' value of 0.85 is 70.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrivon Therapeutics's current PB Ratio of 0.85 is 70.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Acrivon Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current PB Ratio is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current PB Ratio of 0.85. The current PB Ratio is 0.85 and 70.7% below the Biotechnology industry median of 2.91. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current PB Ratio is 0.85 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
